The acceptable PK profile and in vivo efficacy again provided additional rationale to further develop this compound as a supplementary to the current anti-BCR-ABL positive CML therapy. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.